Charles River Labs Intl Stock
Charles River Labs Intl Stock
Charles River Labs Intl gained 2.260% today.
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
With a target price of 165 € there is a slightly positive potential of 10.52% for Charles River Labs Intl compared to the current price of 149.3 €.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | 2.260% | 8.582% | -1.191% | 7.256% | -13.524% | -19.757% | -39.798% |
| United Therapeutics | -1.710% | 11.672% | 20.347% | 79.930% | 20.009% | 155.378% | 258.601% |
| Ionis Pharmaceuticals Inc. | 2.430% | 6.562% | -4.918% | 132.915% | -4.414% | 96.998% | 69.431% |
| Novocure Ltd | 0.710% | -5.490% | -18.320% | -42.790% | -16.771% | -82.993% | -91.633% |
Comments
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Show more
Ratings data for CRL provided by MarketBeat